These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 15215092)

  • 1. Model system for high-throughput screening of novel human immunodeficiency virus protease inhibitors in Escherichia coli.
    Cheng TJ; Brik A; Wong CH; Kan CC
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2437-47. PubMed ID: 15215092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease.
    Ohtaka H; Velázquez-Campoy A; Xie D; Freire E
    Protein Sci; 2002 Aug; 11(8):1908-16. PubMed ID: 12142445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for HIV protease inhibitors by protection against activity-mediated cytotoxicity in Escherichia coli.
    Cheng YS; Lo KH; Hsu HH; Shao YM; Yang WB; Lin CH; Wong CH
    J Virol Methods; 2006 Oct; 137(1):82-7. PubMed ID: 16849028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Escherichia coli expression assay and screen for human immunodeficiency virus protease variants with decreased susceptibility to indinavir.
    Melnick L; Yang SS; Rossi R; Zepp C; Heefner D
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3256-65. PubMed ID: 9835523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.
    Friedler A; Blumenzweig I; Baraz L; Steinitz M; Kotler M; Gilon C
    J Mol Biol; 1999 Mar; 287(1):93-101. PubMed ID: 10074409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using Hierarchical Virtual Screening To Combat Drug Resistance of the HIV-1 Protease.
    Li N; Ainsworth RI; Ding B; Hou T; Wang W
    J Chem Inf Model; 2015 Jul; 55(7):1400-12. PubMed ID: 25993532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of a new cell line inducibly expressing HIV-1 protease for performing safe and highly sensitive screening of HIV protease inhibitors.
    Fuse T; Watanabe K; Kitazato K; Kobayashi N
    Microbes Infect; 2006 Jun; 8(7):1783-9. PubMed ID: 16815068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. beta-Galactosidase containing a human immunodeficiency virus protease cleavage site is cleaved and inactivated by human immunodeficiency virus protease.
    Baum EZ; Bebernitz GA; Gluzman Y
    Proc Natl Acad Sci U S A; 1990 Dec; 87(24):10023-7. PubMed ID: 2124694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro synthesis of enzymatically active HIV-1 protease for rapid phenotypic resistance profiling.
    Hoffmann D; Buchberger B; Nemetz C
    J Clin Virol; 2005 Apr; 32(4):294-9. PubMed ID: 15780808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Establishment of a microbial assay for screening anti-human immunodeficiency virus type-1 protease inhibitors].
    Leng Q; Tao P; Wang L; Gao Q
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1999 Apr; 21(2):140-5. PubMed ID: 12569671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A quick diversity-oriented amide-forming reaction to optimize P-subsite residues of HIV protease inhibitors.
    Brik A; Lin YC; Elder J; Wong CH
    Chem Biol; 2002 Aug; 9(8):891-6. PubMed ID: 12204688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A rapid screening method for biological activity of human immunodeficiency virus proteinase inhibitors by using a recombinant DNA-derived bacterial system.
    Sedlácek J; Fábry M; Horejsí M; Brynda J; Luftig RB; Majer P
    Anal Biochem; 1993 Dec; 215(2):306-9. PubMed ID: 8122796
    [No Abstract]   [Full Text] [Related]  

  • 13. A heterologous substrate assay for the HIV-1 protease engineered in Escherichia coli.
    Stebbins J; Deckman IC; Richardson SB; Debouck C
    Anal Biochem; 1996 Nov; 242(1):90-4. PubMed ID: 8923970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A rapid and sensitive bacterial assay to determine the inhibitory effect of 'interface' peptides on HIV-1 protease co-expressed in Escherichia coli.
    Ast O; Jentsch KD; Schramm HJ; Hunsmann G; Lüke W; Petry H
    J Virol Methods; 1998 Mar; 71(1):77-85. PubMed ID: 9628224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.
    Hazen R; Harvey R; Ferris R; Craig C; Yates P; Griffin P; Miller J; Kaldor I; Ray J; Samano V; Furfine E; Spaltenstein A; Hale M; Tung R; St Clair M; Hanlon M; Boone L
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3147-54. PubMed ID: 17620375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a set of HIV-1 protease inhibitors using binding kinetics data from a biosensor-based screen.
    Hämäläinen MD; Markgren PO; Schaal W; Karlén A; Classon B; Vrang L; Samuelsson B; Hallberg A; Danielson UH
    J Biomol Screen; 2000 Oct; 5(5):353-60. PubMed ID: 11080694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitive genetic screen for protease activity based on a cyclic AMP signaling cascade in Escherichia coli.
    Dautin N; Karimova G; Ullmann A; Ladant D
    J Bacteriol; 2000 Dec; 182(24):7060-6. PubMed ID: 11092869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones.
    Weinheimer S; Discotto L; Friborg J; Yang H; Colonno R
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3816-24. PubMed ID: 16127058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study.
    Dandache S; Coburn CA; Oliveira M; Allison TJ; Holloway MK; Wu JJ; Stranix BR; Panchal C; Wainberg MA; Vacca JP
    J Med Virol; 2008 Dec; 80(12):2053-63. PubMed ID: 19040279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein promiscuity: drug resistance and native functions--HIV-1 case.
    Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
    J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.